OpenURL Connection Search

Select item for more details and to access through your institution.

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.
Published in:
Frontiers of Medicine, 2021, v. 15, n. 3, p. 486, doi. 10.1007/s11684-020-0824-3
By:
- Wang, Dongsheng;
- Fu, Binqing;
- Peng, Zhen;
- Yang, Dongliang;
- Han, Mingfeng;
- Li, Min;
- Yang, Yun;
- Yang, Tianjun;
- Sun, Liangye;
- Li, Wei;
- Shi, Wei;
- Yao, Xin;
- Ma, Yan;
- Xu, Fei;
- Wang, Xiaojing;
- Chen, Jun;
- Xia, Daqing;
- Sun, Yubei;
- Dong, Lin;
- Wang, Jumei
Publication type:
Article
Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events.
Published in:
Cancer Medicine, 2023, v. 12, n. 19, p. 20015, doi. 10.1002/cam4.6556
By:
- Peng, Zhen;
- Wang, Chongwei;
- Sun, Yubei;
- Ma, Yan;
- Wang, Jumei;
- Xu, Fei;
- Xu, Xiaoling;
- Chen, Yin
Publication type:
Article
Paraoxonase 3 is involved in the multi-drug resistance of esophageal cancer.
Published in:
Cancer Cell International, 2018, v. 18, n. 1, p. N.PAG, doi. 10.1186/s12935-018-0657-1
By:
- Huang, Dabing;
- Wang, Yong;
- He, Yifu;
- Wang, Gang;
- Wang, Wei;
- Han, Xinghua;
- Sun, Yubei;
- Lin, Lin;
- Shan, Benjie;
- Shen, Guodong;
- Cheng, Min;
- Bian, Geng;
- Fang, Xiang;
- Hu, Shilian;
- Pan, Yueyin
Publication type:
Article
MiR-20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells.
Published in:
Cancer Cell International, 2017, v. 17, p. 1, doi. 10.1186/s12935-017-0389-7
By:
- Dabing Huang;
- Geng Bian;
- Yueyin Pan;
- Xinghua Han;
- Yubei Sun;
- Yong Wang;
- Guodong Shen;
- Min Cheng;
- Xiang Fang;
- Shilian Hu
Publication type:
Article

Found: 4

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.

Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events.

Paraoxonase 3 is involved in the multi-drug resistance of esophageal cancer.

MiR-20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells.